Imugene highlights azer-cel progress as trial patient enters remission
Imugene highlights azer-cel progress as trial patient enters remission
4 weeks ago
YahooProactive
Imugene secures $2.7m R&D tax refund to support clinical programs
Imugene secures $2.7m R&D tax refund to support clinical programs
1 month ago
YahooProactive
FDA backs Imugene’s azer-cel treatment plan - ICYMI
FDA backs Imugene’s azer-cel treatment plan - ICYMI
3 months ago
proactiveinvestors.com
Leslie Chong on Imugene’s 83% Response Rates Path to FDA Approval | Fear Greed | Imugene Limited
Leslie Chong on Imugene’s 83% Response Rates Path to FDA Approval | Fear Greed | Imugene Limited
9.9K views2 weeks ago
linkedin.com
Imugene highlights azer-cel progress as trial patient enters remission
Imugene highlights azer-cel progress as trial patient enters remission
4 weeks ago
proactiveinvestors.com.au
Imugene secures $2.7m R&D tax refund to support clinical programs
Imugene secures $2.7m R&D tax refund to support clinical programs
1 month ago
proactiveinvestors.co.uk
Imugene with Proactive at ASX Small and Mid Cap Conference
Imugene with Proactive at ASX Small and Mid Cap Conference
Mar 26, 2024
proactiveinvestors.com.au
Imugene teams with ABL to bring VAXINIA into next clinical chapter
Oct 18, 2022
proactiveinvestors.com.au
Imugene doses first combination patient in lung cancer clinical trial
May 31, 2023
proactiveinvestors.com.au
Imugene has cancer vaccine trial data published in prestigious medical journal
5 months ago
proactiveinvestors.com.au
Imugene advances to cohort three of VAXINIA monotherapy dose escalation trial
Apr 4, 2023
proactiveinvestors.com.au
Imugene to open new PD1-Vaxx Phase 2 bowel cancer clinical trial in UK and Australia
Dec 5, 2023
proactiveinvestors.com.au
Imugene welcomes positive FDA feedback on improved manufacturing process for T-cell therapy azer-cel
Sep 10, 2023
proactiveinvestors.com.au
Imugene receives positive early results, including a 'complete response', in Phase 1 VAXINIA study
6 months ago
proactiveinvestors.com
Imugene well positioned to deliver 2024 milestones
Dec 29, 2023
proactiveinvestors.com.au
Imugene talks VAXINIA MAST trial and corporate ambition
Sep 4, 2023
proactiveinvestors.com.au
Imugene thrilled as VAXINIA granted FDA Fast Track designation
Nov 27, 2023
proactiveinvestors.com.au
Imugene’s $20 million boost and cancer trial updates
Feb 2, 2025
proactiveinvestors.com.au
Imugene doses first patient in Phase 2 clinical trial
2 viewsSep 8, 2022
proactiveinvestors.com.au
Imugene off to strong start to 2023 with JP Morgan Healthcare Conference
Jan 22, 2023
proactiveinvestors.com.au
Imugene sees positive early signals in Phase 1 VAXINIA study
Nov 5, 2023
proactiveinvestors.com.au
Groundbreaking cancer trial: Imugene’s CF33 advances in clinical success
Nov 13, 2024
proactiveinvestors.com.au
Imugene achieves ‘complete response’ with mid dose cancer trial
Jan 19, 2024
proactiveinvestors.com
Imugene gets development roadmap for cancer vaccine from FDA meeting
Mar 20, 2019
proactiveinvestors.com.au
Just the Facts: Imugene receives Orphan Drug Designation for VAXINIA from FDA
Sep 19, 2024
proactiveinvestors.com.au
Imugene expands bile tract cancer study as patient shows complete response during MAST trial phase
Apr 15, 2024
proactiveinvestors.com.au
Imugene trial: 75% response rate in diffuse large B-cell lymphoma
8 months ago
proactiveinvestors.com.au
Imugene’s Phase 1 onCARlytics clinical trial doses first patient in intravenous monotherapy arm
Feb 14, 2024
proactiveinvestors.com.au
Imugene secures IND approval for first-in-class onCARlytics trial
May 19, 2023
proactiveinvestors.com
Imugene secures FDA orphan drug designation for bile tract cancer treatment
Sep 18, 2024
proactiveinvestors.com.au
See more